In conclusion, our data show that protein-based PLC-γ1 inhibitors are not only potent PLC-γ1 inhibitors but also possess antitumour effects on EGFR/c-erbB-2-positive breast cancer cells due to the inhibition of both proliferation and migration. Here, PLCG1 is linked to breast carcinoma.